Betaine (TMG): The Methyl Donor That Lowers Homocysteine and Boosts Performance

Betaine — also called trimethylglycine (TMG) because it carries three methyl groups on a glycine backbone — is one of those rare supplements with credible evidence in two completely separate domains: cardiovascular risk reduction via homocysteine lowering, and athletic performance via osmotic and anabolic mechanisms. Neither effect is subtle or requires cherry-picked data to observe. Yet betaine remains vastly underappreciated compared to more aggressively marketed competitors.

Found naturally in beets, spinach, quinoa, and wheat germ, betaine is also synthesized from choline via the enzyme choline dehydrogenase. It functions as both an osmoprotectant — protecting cells against osmotic stress — and a methyl group donor in the methionine cycle, where it converts homocysteine to methionine. That dual role explains why its evidence base spans cardiology and exercise physiology.

Homocysteine Lowering: The Cardiovascular Case

Elevated plasma homocysteine is an independent risk factor for cardiovascular disease, stroke, and venous thromboembolism. Betaine is one of the most potent dietary agents for lowering homocysteine. A meta-analysis of 8 RCTs involving 694 participants found that betaine supplementation at 4–6 g/day reduced fasting homocysteine by a mean of 1.1 mmol/L (about 9–12% reduction) — a magnitude comparable to moderate folate supplementation. Post-methionine-load homocysteine (a more sensitive measure) fell by 23% on average, which is clinically meaningful.

Whether homocysteine lowering per se translates to reduced cardiovascular events remains debated. Several large trials (HOPE-2, VITATOPS) showed folate/B12 supplementation lowered homocysteine without reducing major cardiovascular events over 3–7 years. Betaine-specific cardiovascular endpoint trials do not yet exist. However, betaine's additional roles — liver fat reduction, osmotic cell protection, and anti-inflammatory effects — may offer cardiovascular benefit through pathways independent of homocysteine.

Non-Alcoholic Fatty Liver Disease

Betaine is one of the better-studied nutritional interventions for non-alcoholic fatty liver disease (NAFLD). It donates methyl groups for phosphatidylcholine synthesis (essential for hepatic lipid export), and low betaine status is associated with greater liver fat accumulation in epidemiological studies. A 12-month RCT in NAFLD patients found betaine supplementation (20 g/day) significantly reduced liver fat, ALT, and hepatic fibrosis scores versus placebo — though this high-dose trial predates modern NAFLD staging and warrants replication. Smaller trials using 6–9 g/day showed modest but consistent liver enzyme reductions.

Athletic Performance: A Surprisingly Robust Signal

The sports performance case for betaine is built primarily on osmotic and protein synthesis mechanisms. As an osmolyte, betaine protects muscle cells during dehydration and high-intensity exercise, similar to how creatine functions. As a methyl donor, it supports creatine biosynthesis — supplementation with betaine measurably increases muscle creatine content in some studies, providing a secondary performance pathway.

A 2013 study by Cholewa et al. found that 2.5 g/day of betaine for 6 weeks significantly increased muscle mass (1.8 kg lean mass gain vs. 1.1 kg for placebo) and upper-body power in trained males. A subsequent study from the same group showed improvements in squat and bench press volume. A 2014 meta-analysis confirmed significant effects on muscle power but found inconsistent results for endurance performance. The effective dose across these trials is consistently 2.5 g/day — a dose easily achievable through supplementation. Timing does not appear critical; morning or pre-workout dosing both appear effective.

Safety and Practical Considerations

Betaine has a strong safety profile at doses up to 6 g/day in most populations. Higher doses (above 6 g/day) cause fishy body odor in some individuals due to trimethylamine production — a dose-limiting side effect that can be managed by dividing doses or reducing intake. Individuals with a rare genetic condition called trimethylaminuria are particularly susceptible. GI upset (nausea, diarrhea) is occasionally reported at high doses.

One important caveat: betaine raises LDL cholesterol. A meta-analysis found a dose-dependent increase of approximately 0.36 mmol/L per gram of betaine — a potentially unfavorable effect in people with already-elevated LDL. This needs to be weighed against the homocysteine-lowering benefit in cardiovascular risk assessment.

For most adults, 2.5 g/day is the performance-optimized dose and 6 g/day is the ceiling for cardiovascular applications. Take with food to reduce GI discomfort. Betaine and folate/B12 work synergistically to lower homocysteine — they act through different pathways and stack well. If you're primarily targeting homocysteine reduction, ensuring adequate folate, B12, and B6 status before adding betaine is the rational approach.